TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-Eingaben (vergleichbare Manager):
Halterbreite +5.0% ·
Aktienfluss +7.1% ·
neue Nettopositionen 0.0%
· Formel
Breite Akkumulation: steigende Aktienanzahl bei mehr Inhabern
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q3 2025
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.15M | $67.79M | n/a | −1 |
| Q2 2026 | 113 | +16 | 68.20M | $3.64B | +20 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | n/a |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | n/a | n/a |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | n/a | 10.32M | $84.85M | n/a | n/a |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passiv) | 8.10M | -0.8% | $193.60M | 0.0% | ▼ Trim | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passiv) | 6.61M | +10.3% | $158.06M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | Adage Capital Partners ✦ | 3.55M | +27.6% | $84.89M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passiv) | 3.22M | -7.6% | $76.91M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 2.89M | +171.1% | $69.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 6 | Geode Capital Management ✦ (passiv) | 2.14M | +6.7% | $51.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 1.75M | -29.8% | $41.88M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 8 | Goldman Sachs Group ✦ | 1.27M | n/a | $30.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Wellington Management ✦ | 1.20M | +3331.9% | $28.72M | 0.0% | ▲ Add | 4 | SEC ↗ ×7 |
| 10 | Morgan Stanley ✦ | 1.12M | n/a | $26.70M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 11 | JPMorgan Chase ✦ | 987.68K | n/a | $23.61M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 12 | Two Sigma Investments ✦ | 929.00K | +1.1% | $22.20M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 663.25K | -41.3% | $15.85M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Marshall Wace ✦ | 590.05K | -20.6% | $14.10M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | Arrowstreet Capital ✦ | 328.65K | Neu | $7.85M | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 313.38K | +37.4% | $7.49M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 17 | Millennium Management ✦ | 133.87K | -36.0% | $3.20M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 79.44K | +11.3% | $1.90M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 59.75K | -91.6% | $1.43M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | Fisher Asset Management ✦ | 39.34K | -8.9% | $940,249 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 27.74K | Neu | $663,058 | 0.0% | New | 1 | SEC ↗ |
„Ihr Gewicht" = Anteil der Position am gemeldeten 13F-Aktienwert des Managers: das Überzeugungsmaß. ✦ = kuratorisch betreuter Manager.
Neue Käufer
| Arrowstreet Capital | $7.85M | 0.0% |
| Gotham Asset Management | $663,058 | 0.0% |
Ausgestiegen
| Point72 Asset Management | $2.48M | war 0.0% |
| Norges Bank | $1.05M | war 0.0% |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 1 Inhaber, 121.20K Anteile, $3,600 gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten: gemeinsame Eigentümerzahlen, keine fundamentalen Beziehungen.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer, Director · 78.40K Ant. · $4.31M
Officer, Director · 37.27K Ant. · $2.02M
Officer, Director · 128.06K Ant. · $6.78M
Officer · 8.28K Ant. · $538,917
Officer, Director · 101.69K Ant. · $6.57M
Officer, Director · 6.80K Ant. · $441,795
Officer, Director · 99.72K Ant. · $6.31M
Officer · 79.11K Ant. · $5.04M
Officer · 93.60K Ant. · $5.92M
Officer, Director · 96.12K Ant. · $6.12M
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik